[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, CF Chang, CY Huang, CT Yang… - BMC …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC Cancer, 2021 - go.gale.com
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
CE Wu, CF Chang, CY Huang, CT Yang… - BMC …, 2021 - search.ebscohost.com
Abstract < bold> Background: </bold> Afatinib is one of the standard treatments for
patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer …
patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
CE Wu, CF Chang, CY Huang, CT Yang, CS Kuo… - BMC Cancer, 2021 - europepmc.org
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC Cancer, 2021 - ncbi.nlm.nih.gov
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang… - BMC …, 2021 - bmccancer.biomedcentral.com
Afatinib is one of the standard treatments for patients with epidermal growth factor receptor
(EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib …
(EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, C Ching-Fu, H Chen-Yang, Y Cheng-Ta… - BMC …, 2021 - search.proquest.com
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
CE Wu, CF Chang, CY Huang, CT Yang… - BMC …, 2021 - pure.lib.cgu.edu.tw
Background: Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
[PDF][PDF] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - 2021 - bmccancer.biomedcentral.com
Background: Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …